ORIC Valuation

Oric Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

11.150

+0.09(0.814%)1D

Overview
Forecast
Valuation
Earnings

ORIC Relative Valuation

ORIC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ORIC is overvalued; if below, it's undervalued.

Historical Valuation

Oric Pharmaceuticals Inc (ORIC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.85. The fair price of Oric Pharmaceuticals Inc (ORIC) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：11.15

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

3.58

P/B

Median3y

1.75

Median5y

2.13

-12.40

FCF Yield

Median3y

-25.86

Median5y

-20.92

Competitors Valuation Multiple

The average P/S ratio for ORIC's competitors is 224.24, providing a benchmark for relative valuation. Oric Pharmaceuticals Inc Corp (ORIC) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ORIC.O

Oric Pharmaceuticals Inc

Loss

Average P/S: 224.24

950.25M